Full Press Release Details
Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum
AUSTRALIA AND SAN FRANCISCO, USA - 3 January 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or
"the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases,
today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience
Innovation Forum (NIF). The forum is taking place Sunday, January 8, 2022, as part of the activities surrounding the annual J.P. Morgan
Healthcare Conference.
the conference, Dr. Stamler will be featured on a panel entitled, "New Approaches to Parkinson's and Movement Disorders."
He will also present a company update and participate in investor and business development meetings.
program for the 6th Annual NIF is designed to cover the latest developments in global bio- partnering and investment, with
additional panels covering scientific advances in key therapeutic areas of neurodegenerative diseases and CNS more broadly, which includes
neuropsychiatry, ophthalmology, neurotech and digital therapeutics.
Alterity Therapeutics Limited
Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative
diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad
drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne,
Australia, and San Francisco, California, USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.
& Additional information
announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Bernarda remy.bernarda@iradvisory.com
press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section
21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as
"expects," "intends," "hopes," "anticipates," "believes," "could,"
"may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive
means of identifying such statements.
factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in
the sections titled "Risk Factors" in the Company's filings with the SEC, including its most recent Annual Report on
Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug
development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug
development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve
risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing,
development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited
to, ATH434, uncertainties relating to the impact of the novel coronavirus (COVID-19) pandemic on the company's business, operations
and employees, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate
therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products
coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the
uncertainty of successfully enforcing the Company's patent rights and the uncertainty of the Company freedom to operate.
forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as
of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral,
that may be made from time to time, whether as a result of new information, future developments or otherwise.